Lobe Sciences Announces Appointment of a New Board of Directors and Executive Management Team
Lobe Sciences (CSE: LOBE, OTCQB: LOBEF), a biopharmaceutical company, has announced significant changes to its leadership structure. At the company's annual general meeting, shareholders elected a new Board of Directors comprising Dr. Frederick D. Sancilio, Dr. Harry Jacobson, and Mr. Wesley Ramjeet. Following this, the Board appointed Dr. Sancilio as Chairman and CEO, replacing the departing CEO Philip Young and COO Baxter Phillips III.
The Board also expanded with the addition of Mr. Rick Goulburn as its fourth member, expected to take on a leadership role in pursuing the company's strategic goals. Additionally, Mr. Jeremy Wright joined as a Board and Executive Advisor to provide guidance on strategic and administrative matters. These changes mark a significant shift in Lobe Sciences' leadership as it continues its focus on developing medicines for diseases with unmet medical needs.
Lobe Sciences (CSE: LOBE, OTCQB: LOBEF), un'azienda biofarmaceutica, ha annunciato importanti cambiamenti nella sua struttura dirigenziale. Durante l'assemblea generale annuale, gli azionisti hanno eletto un nuovo Consiglio di Amministrazione composto dal Dr. Frederick D. Sancilio, dal Dr. Harry Jacobson e dal Sig. Wesley Ramjeet. Successivamente, il Consiglio ha nominato il Dr. Sancilio come Presidente e CEO, sostituendo l'ex CEO Philip Young e l'ex COO Baxter Phillips III.
Il Consiglio si è inoltre ampliato con l'aggiunta del Sig. Rick Goulburn come quarto membro, previsto per assumere un ruolo di leadership nel perseguire gli obiettivi strategici dell'azienda. Inoltre, il Sig. Jeremy Wright si è unito come Consigliere del Consiglio ed Esecutivo per fornire orientamenti su questioni strategiche e amministrative. Questi cambiamenti segnano un significativo cambiamento nella leadership di Lobe Sciences mentre continua a concentrarsi sullo sviluppo di farmaci per malattie con bisogni medici insoddisfatti.
Lobe Sciences (CSE: LOBE, OTCQB: LOBEF), una compañía biofarmacéutica, ha anunciado cambios significativos en su estructura de liderazgo. En la reunión general anual de la compañía, los accionistas eligieron un nuevo Consejo de Administración compuesto por el Dr. Frederick D. Sancilio, el Dr. Harry Jacobson y el Sr. Wesley Ramjeet. Después de esto, el Consejo designó al Dr. Sancilio como Presidente y CEO, reemplazando al CEO saliente Philip Young y al COO Baxter Phillips III.
El Consejo también se expandió con la adición del Sr. Rick Goulburn como su cuarto miembro, quien se espera que asuma un papel de liderazgo en la búsqueda de los objetivos estratégicos de la compañía. Además, el Sr. Jeremy Wright se unió como Consejero del Consejo y Ejecutivo para proporcionar orientación sobre asuntos estratégicos y administrativos. Estos cambios marcan un cambio significativo en el liderazgo de Lobe Sciences mientras continúa enfocándose en desarrollar medicamentos para enfermedades con necesidades médicas insatisfechas.
Lobe Sciences (CSE: LOBE, OTCQB: LOBEF)는 제약 생명공학 회사로서 리더십 구조에 대한 중요한 변화를 발표했습니다. 회사의 연례 총회에서 주주들은 Dr. Frederick D. Sancilio, Dr. Harry Jacobson, Mr. Wesley Ramjeet로 구성된 새로운 이사회를 선출했습니다. 이후 이사회는 Dr. Sancilio를 의장 겸 CEO로 임명하였으며, 이는 이전 CEO인 Philip Young과 COO인 Baxter Phillips III의 후임입니다.
이사회는 또한 Mr. Rick Goulburn을 네 번째 회원으로 추가하여 회사의 전략 목표를 추구하는 리더십 역할을 맡게 될 예정입니다. 추가로, Mr. Jeremy Wright는 이사회 및 경영 고문으로 합류하여 전략적 및 관리적 문제에 대한 조언을 제공합니다. 이러한 변화는 Lobe Sciences의 리더십에서 중요한 전환점을 나타내며, unmet medical needs에 대한 치료제를 개발하는 데 집중하고 있습니다.
Lobe Sciences (CSE: LOBE, OTCQB: LOBEF), une entreprise bio-pharmaceutique, a annoncé des changements significatifs dans sa structure de direction. Lors de l'assemblée générale annuelle de l'entreprise, les actionnaires ont élu un nouveau Conseil d'Administration composé du Dr. Frederick D. Sancilio, du Dr. Harry Jacobson et de M. Wesley Ramjeet. Par la suite, le Conseil a nommé le Dr. Sancilio en tant que Président et CEO, remplaçant l'ancien CEO Philip Young et le COO Baxter Phillips III.
Le Conseil s'est également élargi avec l'ajout de M. Rick Goulburn en tant que quatrième membre, qui devrait jouer un rôle de leadership dans la poursuite des objectifs stratégiques de l'entreprise. De plus, M. Jeremy Wright a rejoint en tant que Conseiller auprès du Conseil et Exécutif pour fournir des conseils sur les questions stratégiques et administratives. Ces changements marquent une transformation significative dans la direction de Lobe Sciences alors qu'elle continue de se concentrer sur le développement de médicaments pour des maladies avec des besoins médicaux non satisfaits.
Lobe Sciences (CSE: LOBE, OTCQB: LOBEF), ein biopharmazeutisches Unternehmen, hat bedeutende Änderungen in seiner Führungsstruktur bekannt gegeben. Auf der jährlichen Hauptversammlung wählten die Aktionäre einen neuen Vorstand, bestehend aus Dr. Frederick D. Sancilio, Dr. Harry Jacobson und Herrn Wesley Ramjeet. Anschließend ernannte der Vorstand Dr. Sancilio zum Vorsitzenden und CEO, der den scheidenden CEO Philip Young und COO Baxter Phillips III ersetzt.
Der Vorstand wurde auch um Herrn Rick Goulburn als viertes Mitglied erweitert, der eine Führungsrolle bei der Verfolgung der strategischen Ziele des Unternehmens übernehmen soll. Darüber hinaus trat Herr Jeremy Wright als Berater des Vorstands und Executive Advisor bei, um bei strategischen und administrativen Angelegenheiten Unterstützung zu bieten. Diese Veränderungen markieren einen bedeutenden Wandel in der Führung von Lobe Sciences, während das Unternehmen weiterhin den Fokus auf die Entwicklung von Medikamenten für Krankheiten mit unerfülltem medizinischem Bedarf legt.
- New Board of Directors elected, potentially bringing fresh perspectives and expertise
- Appointment of Dr. Frederick D. Sancilio as Chairman and CEO, potentially strengthening leadership
- Addition of Mr. Rick Goulburn to the Board, expected to take on a leadership role in strategic pursuits
- Appointment of Mr. Jeremy Wright as Board and Executive Advisor for strategic guidance
- Departure of CEO Philip Young and COO Baxter Phillips III, potentially causing leadership disruption
- Significant management changes may lead to short-term operational challenges
- Annual General Meeting elects new Board of Directors: Dr. Frederick D. Sancilio, Dr. Harry Jacobson and Mr. Wesley Ramjeet
- Board announces resignations of CEO Philip Young and COO Baxter Phillips III
- The Board of Directors appoints Dr. Frederick D. Sancilio as Chairman and CEO of the company
- Mr. Rick Goulburn appointed to the Board as its fourth member
- Mr. Jeremy Wright joins the company as Board Advisor
Dr. Sancilio, Chairman and CEO said, “While I regret the departure of Mr. Young and Mr. Phillips, I am excited about the opportunity to implement plans focused on creating shareholder value while serving the needs of patients with serious unmet medical needs.”
The Company also announces the appointment by the Board of Mr. Rick Goulburn as its fourth member. Mr. Goulburn is expected to take on a leadership role as the Company moves forward toward its strategic goals. Finally, Lobe Sciences announces the appointment of Mr. Jeremy Wright as a Board and Executive Advisor. Mr. Wright will provide guidance to the Company and its Board concerning strategic and administrative issues.
About Lobe Sciences Ltd.
Lobe Sciences is a biopharmaceutical company focused on developing medicines to treat diseases with unmet medical needs. The Company, through collaboration with industry-leading partners, is engaged in novel research and development focused on treating chronic cluster headache (an orphan disease), refractive anxiety, opioid addiction and sickle cell disease. The Company is engaged in Phase 1 and Phase 2 activities in its drug portfolio, and intends to initiate the launch of Altemia®, a medical food designed to meet the needs of sickle cell patients globally.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.
Cautionary Statement Regarding "Forward-Looking" Information
This news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including, without limitation: the Company’s intention to implement plans focused on creating shareholder value while serving the needs of patients with serious unmet medical needs; the anticipated focus of the Company’s research and development activities; and the anticipated launch of Altemia® are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should” or “would” or occur.
Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including, among other things, that: the Company’s planned activities will be able to create shareholder value and address serious unmet medical needs; the Company will continue to pursue its planned research and development activities; and the Company will launch Altemia®. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important risks that may cause actual results to vary, include, without limitation, the risk that: the Company’s planned activities will be unable to create shareholder value or address the targeted unmet medical needs; the Company is unable to obtain the desired results from its current research and development activities; and the Company is unable to launch Altemia® or to do so on the timelines anticipated.
Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240812177123/en/
For further information:
Dr. Fred D. Sancilio, CEO
Lobe Sciences Ltd.
Investor and Media
Info@Lobesciences.com
Source: Lobe Sciences Ltd
FAQ
Who are the new Board members of Lobe Sciences (LOBEF)?
Who is the new CEO of Lobe Sciences (LOBEF)?
What changes occurred in Lobe Sciences' (LOBEF) management team?
What is Lobe Sciences' (LOBEF) main focus as a company?
